Liminatus Pharma LIMN 深 沪
等待开盘 08-28 09:30:00 美东时间
4.40
-0.010
-0.23%
华盛通- 最 高4.88
- 今 开4.37
- 成交量 5.21万股
- 最 低 4.37
- 昨 收 4.41
- 总市值 591.01万
- 52周最高 141.50
- 市盈率 静 --
- 换手率 3.88%
- 52周最低 4.26
- 委 比 46.09%
- 总股本 134.32万
- 历史最高 1683.00
- 量 比 0.07
- 振 幅 11.56%
- 历史最低 4.37
- 每 手 1
- 风险率 34.31%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate
Liminatus Pharma, Inc. (NASDAQ:LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has engaged Synex Consulting Ltd. ("Synex"), a Korea-based full-service contract research organization ("CRO"), to support the clinical develop...
08-24 20:01
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
Liminatus Pharma has engaged Synex Consulting to support the clinical development of IBC101, a CD19xCD22 bivalent CAR-T therapy for relapsed or refractory B-cell malignancies, in South Korea. IBC101 has received MFDS authorization for a Phase 1/2a study in DLBCL patients, with Synex providing milestone-based clinical services. The collaboration aims to advance IBC101 toward clinical execution, leveraging Synex's local expertise. IBC101 targets CD...
08-24 12:00
Liminatus Pharma shares are trading higher after the company announced its stock transfer to the Nasdaq Capital Market and an extension to meet minimum bid price compliance.
Liminatus Pharma shares are trading higher after the company announced its stock transfer to the Nasdaq Capital Market and an extension to meet minimum bid price compliance.
08-14 02:58
Liminatus Pharma Shareholders Approve Reverse Stock Split Plan
An announcement from Liminatus Pharma ( ($LIMN) ) is now available. On August 3...
08-05 05:37
11 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's regular session. The market value of their outstanding shares is at $12.2 million. Liminatus Pharma (NASDAQ:LIMN) shares rose 26.04% to $0.14. The market value of their outstanding shares is at $5.8 milli...
07-03 01:05
Liminatus Pharma Amends Proposed $320M Merger Deal With InnocsAI As Closing Now Anticipated Before Shareholder Approval On July 2
Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amended and restated the previously announced definitive merger agreement with InnocsAI LLC ("InnocsAI"), an oncology biotechnology compan...
07-01 04:32
Liminatus Pharma secures $1.9M cash via warrant exercises
Liminatus Pharma (LIMN) has entered into a warrant exercise agreement to exercise certain outstanding warrants to purchase an aggregate of 10.34M shares of common stock of the company for gross procee...
06-03 21:14
Liminatus Pharma Enters Warrant Exercise Agreement With Existing Investors To Purchase 10,344,000 Shares At $0.18 Per Share
In consideration for the immediate exercise of the Existing Warrants for cash, the exercising holders were issued new unregistered warrants to purchase an aggregate of 20,688,000 million shares of common stock (the "New
06-03 20:33
